Japan Pharmaceutical Trade Association Helps Foot Bill To Speed Up Approval Of Drugs Pending Approval
This article was originally published in PharmAsia News
Executive Summary
The Japan Pharmaceutical Manufacturer's Association announced a plan to establish a support center to speed up approvals of drugs not yet approved in Japan. With an annual budget of ¥310 million and staffed with Japanese academics and pharmaceutical industry veterans, the center is opening its doors this month
You may also be interested in...
MHLW To Add 100 Adverse Event Analysts
Japan's Ministry of Health, Labor and Welfare has put out a new plan to recruit 100 drug adverse effect analysts to strengthen such functions at the Pharmaceutical and Medical Device Agency. PMDA handles drug reviews and post market inspections. The increase will more than double the current 66 analysts who are conducting side effects analysis. The Ministry expects most of the new hires will be physicians, pharmacists and statisticians. As several highly effective cancer and rheumatic drugs have been launched to the market, the Ministry estimates that associated adverse events reports will be on the rise. (Click here for more - Japanese language
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).